Deacetylase Inhibitors Dissociate the Histone-Targeting ING2 Subunit from the Sin3 Complex

Chemistry and Biology

Volumn 17, Issue 1, 2010, Pages 65-74

  Smith, Karen T ^a   Martin Brown, Skylar A ^a   Florens, Laurence ^a   Washburn, Michael P ^a,b   Workman, Jerry L ^a  

^a STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

CELLBIO; CHEMBIO; DNA

Indexed keywords

CELL RECEPTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HOMEODOMAIN PROTEIN; HYDROXAMIC ACID; ING2 PROTEIN, HUMAN; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN; VORINOSTAT;

ARTICLE; CELL LINE; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; PROMOTER REGION;

CELL LINE; HISTONE DEACETYLASE INHIBITORS; HOMEODOMAIN PROTEINS; HUMANS; HYDROXAMIC ACIDS; PROMOTER REGIONS, GENETIC; RAS PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIN3 HISTONE DEACETYLASE AND COREPRESSOR COMPLEX; TUMOR SUPPRESSOR PROTEINS;

EID: 75149132122     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2009.12.010     Document Type: Article

References (47)

1. Alland L., David G., Shen-Li H., Potes J., Muhle R., Lee H.C., Hou Jr. H., Chen K., and DePinho R.A. Identification of mammalian Sds3 as an integral component of the Sin3/histone deacetylase corepressor complex. Mol. Cell. Biol. 22 (2002) 2743-2750
2. Balasubramanian S., Verner E., and Buggy J.J. Isoform-specific histone deacetylase inhibitors: the next step?. Cancer Lett. 280 (2009) 211-221
3. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., and Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325 (2009) 834-840
4. David G., Turner G.M., Yao Y., Protopopov A., and DePinho R.A. mSin3-associated protein, mSds3, is essential for pericentric heterochromatin formation and chromosome segregation in mammalian cells. Genes Dev. 17 (2003) 2396-2405
5. Denslow S.A., and Wade P.A. The human Mi-2/NuRD complex and gene regulation. Oncogene 26 (2007) 5433-5438
6. Doyon Y., Cayrou C., Ullah M., Landry A.J., Cote V., Selleck W., Lane W.S., Tan S., Yang X.J., and Cote J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 21 (2006) 51-64
7. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
8. Frew A.J., Johnstone R.W., and Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 280 (2009) 125-133
9. Glaser K.B., Li J., Staver M.J., Wei R.Q., Albert D.H., and Davidsen S.K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 310 (2003) 529-536
10. Gozani O., Karuman P., Jones D.R., Ivanov D., Cha J., Lugovskoy A.A., Baird C.L., Zhu H., Field S.J., Lessnick S.L., et al. The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell 114 (2003) 99-111
11. Gui C.Y., Ngo L., Xu W.S., Richon V.M., and Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 101 (2004) 1241-1246
12. Haberland M., Johnson A., Mokalled M.H., Montgomery R.L., and Olson E.N. Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl. Acad. Sci. USA 106 (2009) 7751-7755
13. Hassig C.A., Tong J.K., Fleischer T.C., Owa T., Grable P.G., Ayer D.E., and Schreiber S.L. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc. Natl. Acad. Sci. USA 95 (1998) 3519-3524
14. Huang L., and Pardee A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 6 (2000) 849-866
15. Khan O., and La Thangue N.B. Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat. Clin. Pract. Oncol. 5 (2008) 714-726
16. Lai A., Kennedy B.K., Barbie D.A., Bertos N.R., Yang X.J., Theberge M.C., Tsai S.C., Seto E., Zhang Y., Kuzmichev A., et al. RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest. Mol. Cell. Biol. 21 (2001) 2918-2932
17. Lin Y.C., Lin J.H., Chou C.W., Chang Y.F., Yeh S.H., and Chen C.C. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res. 68 (2008) 2375-2383
18. Mahrour N., Redwine W.B., Florens L., Swanson S.K., Martin-Brown S., Bradford W.D., Staehling-Hampton K., Washburn M.P., Conaway R.C., and Conaway J.W. Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases. J. Biol. Chem. 283 (2008) 8005-8013
19. Mann B.S., Johnson J.R., Cohen M.H., Justice R., and Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 (2007) 1247-1252
20. Marks P.A., and Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 107 (2009) 600-608
21. Matsuoka H., Fujimura T., Hayashi M., Matsuda K., Ishii Y., Aramori I., and Mutoh S. Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem. Pharmacol. 74 (2007) 465-476
22. Meehan W.J., Samant R.S., Hopper J.E., Carrozza M.J., Shevde L.A., Workman J.L., Eckert K.A., Verderame M.F., and Welch D.R. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J. Biol. Chem. 279 (2004) 1562-1569
23. Menendez C., Abad M., Gomez-Cabello D., Moreno A., and Palmero I. ING proteins in cellular senescence. Curr. Drug Targets 10 (2009) 406-417
24. Nagashima M., Shiseki M., Miura K., Hagiwara K., Linke S.P., Pedeux R., Wang X.W., Yokota J., Riabowol K., and Harris C.C. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl. Acad. Sci. USA 98 (2001) 9671-9676
25. Nikolaev A.Y., Papanikolaou N.A., Li M., Qin J., and Gu W. Identification of a novel BRMS1-homologue protein p40 as a component of the mSin3A/p33ING1b/HDAC1 deacetylase complex. Biochem. Biophys. Res. Commun. 323 (2004) 1216-1222
26. Paoletti A.C., Parmely T.J., Tomomori-Sato C., Sato S., Zhu D., Conaway R.C., Conaway J.W., Florens L., and Washburn M.P. Quantitative proteomic analysis of distinct mammalian Mediator complexes using normalized spectral abundance factors. Proc. Natl. Acad. Sci. USA 103 (2006) 18928-18933
27. Pena P.V., Hom R.A., Hung T., Lin H., Kuo A.J., Wong R.P., Subach O.M., Champagne K.S., Zhao R., Verkhusha V.V., et al. Histone H3K4me3 binding is required for the DNA repair and apoptotic activities of ING1 tumor suppressor. J. Mol. Biol. 380 (2008) 303-312
28. Pile L.A., Schlag E.M., and Wassarman D.A. The SIN3/RPD3 deacetylase complex is essential for G(2) phase cell cycle progression and regulation of SMRTER corepressor levels. Mol. Cell. Biol. 22 (2002) 4965-4976
29. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97 (2000) 10014-10019
30. Schuetz A., Min J., Allali-Hassani A., Schapira M., Shuen M., Loppnau P., Mazitschek R., Kwiatkowski N.P., Lewis T.A., Maglathin R.L., et al. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 283 (2008) 11355-11363
31. Sekhavat A., Sun J.M., and Davie J.R. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem. Cell Biol. 85 (2007) 751-758
32. Seraj M.J., Samant R.S., Verderame M.F., and Welch D.R. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 60 (2000) 2764-2769
33. Shi X., Hong T., Walter K.L., Ewalt M., Michishita E., Hung T., Carney D., Pena P., Lan F., Kaadige M.R., et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 442 (2006) 96-99
34. Sironi E., Cerri A., Tomasini D., Sirchia S.M., Porta G., Rossella F., Grati F.R., and Simoni G. Loss of heterozygosity on chromosome 4q32-35 in sporadic basal cell carcinomas: evidence for the involvement of p33ING2/ING1L and SAP30 genes. J. Cutan. Pathol. 31 (2004) 318-322
35. Smith C.L. A shifting paradigm: histone deacetylases and transcriptional activation. Bioessays 30 (2008) 15-24
36. Smith K.T., and Workman J.L. Histone deacetylase inhibitors: anticancer compounds. Int. J. Biochem. Cell Biol. 41 (2009) 21-25
37. Spange S., Wagner T., Heinzel T., and Kramer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 41 (2009) 185-198
38. Unoki M., Kumamoto K., and Harris C.C. ING proteins as potential anticancer drug targets. Curr. Drug Targets 10 (2009) 442-454
39. Van Lint C., Emiliani S., and Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5 (1996) 245-253
40. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., Chakravarty P., Paolini C., De Francesco R., Gallinari P., et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA 101 (2004) 15064-15069
41. Vermeulen M., Carrozza M.J., Lasonder E., Workman J.L., Logie C., and Stunnenberg H.G. In vitro targeting reveals intrinsic histone tail specificity of the Sin3/histone deacetylase and N-CoR/SMRT corepressor complexes. Mol. Cell. Biol. 24 (2004) 2364-2372
42. Viiri K.M., Janis J., Siggers T., Heinonen T.Y., Valjakka J., Bulyk M.L., Maki M., and Lohi O. DNA-binding and -bending activities of SAP30L and SAP30 are mediated by a zinc-dependent module and monophosphoinositides. Mol. Cell. Biol. 29 (2009) 342-356
43. Wang Y., Zhang H., Chen Y., Sun Y., Yang F., Yu W., Liang J., Sun L., Yang X., Shi L., et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138 (2009) 660-672
44. Wiech N.L., Fisher J.F., Helquist P., and Wiest O. Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. Curr. Top. Med. Chem. 9 (2009) 257-271
45. Witt O., Deubzer H.E., Milde T., and Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett. 277 (2009) 8-21
46. Yang X.J., and Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9 (2008) 206-218
47. Yoon H.G., Choi Y., Cole P.A., and Wong J. Reading and function of a histone code involved in targeting corepressor complexes for repression. Mol. Cell. Biol. 25 (2005) 324-335